Figure 1
From: Drug target gene-based analyses of drug repositionability in rare and intractable diseases
Analysis of drug repositioning in rare and intractable diseases based on clinical trial data. (A) Pipeline of extracting information from clinical trials. First, from 412,555 clinical trials in the four registries (JPRN, ClinicalTrials.gov, EU-CTR, and ChiCTR), 15,194 trials which are for rare and intractable diseases and contain drug information were selected. Second, by limiting the drugs to those that have target gene information, 8307 trials containing those drugs were selected. (B) Schema of drug repositioning where a drug in disease A is repositioned to disease B. A drug repositioning occurs when a drug which formerly tested for a disease newly becomes shared. (C) Accumulated number of clinical trials identified as drug repositioning trials enrolled annually in recent 20 years. In total, 1676 clinical trials were identified during the period. (D) Accumulated number of disease pairs combined for drug repositioning first appeared during the period. In total 4401 disease pairs were counted during the period.
